Mirte Scherpenisse

Suggest Changes
Learn More
In 2006/2007, two vaccines were licensed against two of the most common HPV types that cause about 70% of cervical cancers. Clinical trials show that vaccinated individuals develop high levels of(More)
OBJECTIVES In order to assess HPV-specific IgG characteristics, we evaluated multiple aspects of the humoral antibody response that will provide insight in the HPV humoral immune response induced by(More)
In healthy females, human papillomavirus (HPV) vaccines are safe, immunogenic, and effective in inducing protection against HPV16/18 infections and their associated premalignant lesions, especially(More)